Cargando…

Phosphorylation by mTORC1 stablizes Skp2 and regulates its oncogenic function in gastric cancer

BACKGROUND: Both mTOR and Skp2 play critical roles in gastric cancer (GC) tumorigenesis. However, potential mechanisms for the association between these two proteins remains unidentified. METHODS: The regulatory role for mTORC1 in Skp2 stability was tested using ubiquitination assay. The functions o...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Qirong, Liu, Jianjun, Gong, Zhaohui, Chen, Shangxiang, Chen, Shuai, Li, Xiaoxing, Lu, Yue, Zhu, Xiaofeng, Lin, Hui-kuan, Xu, Dazhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407005/
https://www.ncbi.nlm.nih.gov/pubmed/28446188
http://dx.doi.org/10.1186/s12943-017-0649-0
Descripción
Sumario:BACKGROUND: Both mTOR and Skp2 play critical roles in gastric cancer (GC) tumorigenesis. However, potential mechanisms for the association between these two proteins remains unidentified. METHODS: The regulatory role for mTORC1 in Skp2 stability was tested using ubiquitination assay. The functions of p-Skp2 (phosphorylation of Skp2) were studied in vitro and in vivo. Expression of p-Skp2 and p-mTOR (phosphorylation of mTOR) were shown in GC lines and in 169 human primary GC tissues. RESULTS: mTORC1 can directly interact with Skp2 and phosphorylated Skp2 at Ser64, which sequentially protect Skp2 from ubiquitination and degradation. Furthermore, the phospho-deficient p-Skp2 (S64) mutant significantly suppresses GC cell proliferation and tumorigenesis. The expression of p-Skp2 was associated with p-mTOR in GC cell lines and tissues. Interestingly, the combination of p-Skp2 and p-mTOR was a better predictor of survival than either factor alone. CONCLUSION: The mTORC1 function to regulate Skp2 by Ser64 phosphorylation may represent an oncogenic event in GC tumorigenesis. Moreover, our study also indicates that Skp2 Ser64 expression is a potential indicator in the treatment of GC patients using mTORC1 inhibitor. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-017-0649-0) contains supplementary material, which is available to authorized users.